IBRI operates as an independent nonprofit filling the translational gap between academic discovery and commercial drug development, where promising research often stalls. Current research targets rare pediatric cancers including neurofibromatosis and metastatic sarcomas, using data science and molecular innovation to identify biomarkers and develop therapeutics.